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Abstract
Background: Hemophagocytic lymphohistiocytosis is a disease process characterized by unregulated
hyperactivation of the immune system associated with multiorgan involvement and high mortality rates. Early
recognition is crucial and a recently validated diagnostic schema, the H-Score, may facilitate diagnosis particularly in
secondary hemophagocytic lymphohistiocytosis cases. We present a patient with secondary hemophagocytic
lymphohistiocytosis in association with metastatic renal cell carcinoma in whom high-dose steroid therapy induced
a remarkable response.
Case presentation: A 35-year-old Vietnamese man with quiescent systemic lupus erythematosus was diagnosed 5
months prior to admission with left-sided renal cell carcinoma metastatic to the pancreas and spine. Ten days prior
to admission, a febrile illness (temperatures to 39 °C) associated with flu-like symptoms unresponsive to levofloxacin
developed. He took only two doses of pazopanib prior to admission. High fevers unresponsive to antimicrobial
therapy, cytopenias, disseminated intravascular coagulation, and progressive multiorgan failure led to intubation
and intensive care unit stay. Extensive infectious disease workup showed only negative results, but elevation of
interleukin-2 receptor, exceedingly high ferritin levels and other features earned an H-Score of 302, consistent with
>99% diagnostic probability for secondary hemophagocytic lymphohistiocytosis. High-dose steroid therapy
produced a rapid clinical and biochemical response.
Conclusions: Hemophagocytic lymphohistiocytosis is a life-threatening disorder which is likely to be under-
recognized. Increased awareness of this disease entity and its diagnosis is crucial toward early recognition and
treatment. To our knowledge, our patient is only the second reported with secondary hemophagocytic
lymphohistiocytosis occurring in the setting of renal cell carcinoma.
Keywords: Hemophagocytic lymphohistiocytosis, Disseminated intravascular coagulation, Fever, Fever of unknown
origin, Altered mental status
Background
Hemophagocytic lymphohistiocytosis (HLH) is a disease
process characterized by unregulated hyperactivation of the
immune system resulting in variable combinations of fever,
multiorgan involvement (particularly transaminase eleva-
tion), and peripheral blood cytopenias [1]. Presentations
are generally divided into primary and secondary forms,
the former typically occurring in infants or young children
and often incorporating either autosomal recessive
mutations in any of several recognized familial hemopha-
gocytic lymphohistocytosis (FHL) genes, or as a feature of
other, non-FHL immunodeficiency syndromes (see
Table 1) [2, 3]. Primary HLH, which has an incidence of
1.2 per million children per year [4], is diagnosed based
upon criteria set forth by the Histiocyte Society [5] (see
Table 1).
Secondary HLH occurs typically in adolescents or
adults and in the setting of infectious, rheumatologic
(i.e., juvenile idiopathic inflammatory arthritis), or ma-
lignant conditions (i.e., lymphoma) [6]. The HLH-2004
criteria may have reduced sensitivity and specificity in
secondary HLH - where sufficient criteria may not be
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met at disease onset but develop later in the course and
associated malignancy and inflammatory conditions
may predispose to higher baseline ferritin values [3]. It
has, therefore, been suggested that this disorder is likely
under-recognized in modern practice [7]. Treatment is
largely based upon the original HLH-94 protocol [8] in-
corporating an initial 8-week induction regimen using
corticosteroids in most patients and chemotherapy
(etoposide) in selected patients (i.e., when Epstein-Barr
virus (EBV)-driven disease is present). Despite treat-
ment, the mortality of secondary HLH ranges from
32.4% to as high as 87.5% [9, 10].
We recently encountered a 35-year-old male patient with
a history of systemic lupus erythematosus (SLE) and meta-
static renal cell carcinoma, who presented with a flu-like ill-
ness. Fevers, multiorgan failure, altered mental status,
cytopenias, and disseminated intravascular coagulation
(DIC) findings progressed rapidly in the face of empiric
antimicrobial and antiviral therapy. Diagnosis of secondary
HLH and immediate institution of corticosteroid therapy
was associated with a dramatic clinical response.
Case presentation
A 35-year-old Vietnamese man with underlying SLE
who was taking hydroxychloroquine, azathioprine, and
prednisone was diagnosed 5 months prior to admission
with metastatic renal cell carcinoma with a 6.6 × 6.0 ×
7.2-cm left renal mass with disruption of fat planes, sug-
gestive of involvement of the tail of the pancreas, as well
as a 4.1 × 3.2 × 2.6-cm mass at the T8 spinal vertebra.
On hospital day (HD) -43, he underwent hemiverteb-
rectomy with fusion of adjacent vertebral levels; patho-
logic examination of the T8-mass demonstrated renal
cell carcinoma. He was first evaluated at our institution
for a second opinion for his malignancy on HD −21.
Plans were put forth to obtain outside records and
undertake multidisciplinary treatment planning during
tumor board.
However, on approximately HD −10, he developed a
febrile illness (temperatures to 38.9 °C measured at
home) with flu-like symptoms comprised of shortness
of breath, frontal headaches, sore throat with neck
pain, nausea, vomiting, diarrhea, and generalized
weakness. He took pazopanib 800 mg daily, which had
been prescribed prior to onset of illness, on HDs −3
and −2. Despite an outpatient course of levofloxacin,
progression of symptoms led ultimately to presenta-
tion on HD 0.
Presenting vital signs in the emergency department
included fever of 39.2 °C, tachycardia of 101 beats per
minute (bpm), and relative hypotension at 106/66
mmHg. Initial laboratory studies demonstrated multior-
gan involvement with pancytopenia, acute kidney in-
jury, hyponatremia, abnormal liver function tests, and
elevations in lactic acid, procalcitonin, and lipase levels.
Clinically, he was judged to be euvolemic. Further stud-
ies noted that serum osmolality was low at 267 mOsm/
kg, spot urine sodium 24 mmol/L, and urine osmolality
776 mOsm/kg. A plain film of the chest was normal, save
for spinal hardware, and cranial computed tomography
showed no acute intracranial process. His SLE was clinically
judged to be quiescent, corroborated by an anti-double-
stranded deoxyribonucleic acid (anti-dsDNA) antibody
screen and an extensive infectious disease workup both of
which showed only negative results (see Table 2).
He was started on broad-spectrum antibiotics (vanco-
mycin and piperacillin-tazobactam) and admitted to the
internal medicine service. On HD 2, given a declining
mental status and concern for meningitis, piperacillin-
tazobactam was discontinued, and ceftriaxone, acyclovir,
and ampicillin were added to the vancomycin. Ultim-
ately, the patient required intubation for airway protec-
tion and was transferred to the medical intensive care
unit (ICU). Lumbar puncture was performed and the re-
sults are presented in Table 2.
On HD 2 he developed urinary retention with a 600-
ml output following straight catheterization prompting
placement of a Foley catheter. Also on HD 2, loose
stools developed along with increased abdominal rigid-
ity and a rise in lactic acid levels from an admission
value of 1.8 mmol/L (normal 0.5–2.2) to 4.9 mmol/L.
Stool polymerase chain reaction (PCR) was negative for
Table 1 Hemophagocytic lymphohistiocytosis (HLH) 2004 diagnostic criteria (Adapted with permission from John Wiley and Sons
Ltd. from Brisse et al. [3] and Henter et al. [5]). Diagnostic criteria 1–5 represent the original 1991 diagnostic criteria; the HLH 2004
revision adds criteria 6–8. The diagnosis of primary HLH can be made either on a molecular or clinical basis
HLH Molecular diagnosis At least 5 of the following 8 diagnostic criteria
FHL genes PRF1, UNC13D, STX11, STXBP2 1. Fever 2. Splenomegaly
3. Cytopenias (≥2/3 lineages)a 4. High triglyceride/low fibrinogen levelsb
Non-FHL genes RAB27A, LYST, AP3B1, SH2D1A, XIAP 5. Hemophagocytosis 6. Low/absent NK-cell activity
7. Ferritin ≥500 ng/mL 8. Soluble IL-2 receptor ≥2400 U/mL
FHL Familial hemophagocytic lymphohistocytosis, NK Natural Killer, and IL Interleukin. non-FHL gene mutations occur in Gricselli syndrome, Chediak-Higashi syn-
drome, Hermansky-Pudlak syndrome type 2, and X-linked lymphoproliferative disease
aHb <9 g/dL, platelets <100 K/mcL, neutrophils <1.0 K/mcL. bTriglycerides ≥265 mg/dL, fibrinogen ≤150 mg/dL
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Clostridium difficile toxin B. His mental status deterio-
rated and he became agitated and required intubation
on HD 2 for airway protection and was transferred to
the medical ICU.
Laboratory values on HD 2 included elevated aspartate
aminotransferase (AST, normal range 13-39 U/L)/alanine
aminotransferase (ALT, normal range 7-52 U/L) of 547
and 118 U/L, respectively; declining albumin from 2.7 to
1.7 mg/dL; and elevated LDH of 2833 U/L (normal 140-
271 U/L), lipase of 501 U/L (normal 11–82 U/L), and tri-
glycerides of 500 mg/dL (normal <150 mg/dL). Iron stud-
ies revealed a low transferrin of 99.3 mg/dL (normal 203–
362 mg/dL) and TIBC of 139 mcg/dL (284–507 mcg/dL),
low-normal serum iron of 50 mcg/dL (normal 49–181
mcg/dL), and normal saturation of 36% (normal 20–55%).
Ferritin was substantially elevated at >7500 ng/mL (nor-
mal 23–233 ng/mL) and later peaked at >15,000 ng/mL.
The Quantiferon Gold tuberculosis (TB) test resulted
as indeterminate due to a high degree of nonspecific re-
activity produced by the patient’s specimen (i.e., NIL
(negative control tube) >10 IU/mL). This was in con-
cert with a very high C-reactive protein (CRP) result of
25.9 mg/dL (normal range 0.0–1.0 mg/dL) and an ele-
vated soluble interleukin (IL)-2 receptor result of 1112
pg/mL (normal ≤1033 pg/mL). A purified protein de-
rivative (PPD) skin test yielded 0-mm induration.
Despite broad-spectrum antibiotics, the patient
remained persistently febrile, with daily fevers exceeding
38.4 °C (maximal temperature was on HD 2 at 38.9 °C).
He developed rigors and a subsequent mild rhabdomyoly-
sis with creatinine kinase values increasing to a maximum
of 7546 U/L (normal 30–223 U/L) on HD 2. Aggressive
cooling measures were required, including acetaminophen
and a cooling blanket. Continuous rigors with abdominal
rigidity precluded accurate physical examination for hepa-
tosplenomegaly. A kidneys-ureters-bladder (KUB) plain
film taken on HD 2, however, had findings consistent with
possible hepatosplenomegaly.
A coagulopathy developed with maximal values on
HD 5 of Prothrombin Time (PT) 29.7 s (normal
11.5–14.1 s), International Normalized Ratio (INR) of
2.91 (0.87–1.13), Partial Thromboplastin Time (PTT)
63.5 s (normal 24.7–37.0 s), and nadir fibrinogen level
of 76 mg/dL (211–410 mg/dL). The latter prompted
cryoprecipitate transfusions on HD 4 and HD 6. Pro-
gression of coagulopathy occurred in parallel with
progression of thrombocytopenia, with nadir platelet
count by HD 9 of 25 K/mcL (normal 150–400 K/
mcL). Nadir hemoglobin also occurred on HD 9 at 7
g/dL. Schistocytosis was absent and neither red blood
cell nor platelet transfusions were required through-
out the hospital stay.


















































CSF showed 14 nucleated cells/mm3
(normal 0–5/mm3) consisting of 84%
polymorphonuclear leukocytes,
9% lymphocytes, and 7% monocytes;
44 mg/dL glucose (normal 41–70 mg/dL);
70 mg/dL protein (normal 15–45 mg/dL)
Cryptococcus
neoformans Ag


























Ab antibody, Ag antigen, CMV cytomegalovirus, EBV Epstein-Barr virus, HSV herpes simplex virus, Ig immunoglobulin, MSSA methicillin-sensitive Staphylococcus aur-
eus, MRSA methicillin-resistant Staphylococcus aureus, PCR polymerase chain reaction, PPD purified protein derivative, RSV respiratory syncytial virus
aEBV viral capsid, nuclear, and early diffuse IgG Abs reactive, viral capsid IgM nonreactive; EBV PCR not performed
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The combination of fever (maximal recorded 39.2 °C) in
the setting of an infectious disease workup which showed
only negative results, with trilineage cytopenias, elevated
AST and ALT, hypofibrinogenemia (nadir of 76 mg/dL),
significant hyperferritinemia (peak >15,000 ng/mL), triglyc-
erides of 500 mg/dL, as well as suggestion on KUB imaging
for hepatosplenomegaly, was compatible with a secondary
HLH diagnosis. Involvement of the central nervous system
(CNS) was evident given his mental status changes and agi-
tation. Additionally, natural killer (NK)-cell function was
reduced with a Lytic Unit 30 value of 5 lytic sets (normal
LU30 = 7–125 lytic sets) and soluble IL-2 receptor level
modestly elevated at 1112 pg/mL (normal ≤1033).
High-dose steroids were, therefore, initiated. Dexa-
methasone, preferred because it can cross the blood-
brain barrier, was initiated at 10 mg/m2 daily for
weeks 1 and 2, followed by 5 mg/m2 daily for weeks 3
and 4, then 2.5 mg/m2 daily for weeks 5 and 6, then
1.25 mg/m2 daily for week 7 with tapering to zero dur-
ing week 8. Clinical response was immediately noted
with resolution of fevers and rigors and rapidly im-
proving mental status. Laboratory abnormalities also
improved; their trends following initiation of dexametha-
sone are further detailed in Fig. 1. Our patient was subse-
quently extubated on HD 5 and discharged in ambulatory
condition with full cognitive ability on HD 20.
Discussion
Our 35-year-old patient developed secondary HLH in the
setting of preexisting immunosuppression due to under-
lying SLE and metastatic renal cell carcinoma. To our
knowledge, this is the first case of HLH reported in the
setting of pazopanib therapy and only the second case re-
ported in association with renal cell carcinoma (RCC) [11].
Based upon a validated cohort of secondary HLH pa-
tients [12], Fardet et al. developed a diagnostic H-Score
[13] to predict the likelihood of secondary HLH. Points
are assigned based upon presence of:
 Three clinical features
○ Known immunosuppression – no: 0/yes: 18;
high temperature <38.4 °C: 0, 38.4 to 39.4 °C:
33, >39.4 °C: 49; neither hepatomegaly nor
splenomegaly: 0, either: 23, or both: 38
Fig. 1 Timeline. Improvement in laboratory values with initiation of dexamethasone. PLT platelet count (normal 150–400 K/mcL), AST aspartate
aminotransferase (normal 13–39 U/L), CK creatinine kinase (normal 30–223 U/L)
El-Masry et al. Journal of Medical Case Reports  (2017) 11:56 Page 4 of 6
 Five biologic features
○ Triglycerides mg/dL <132.9: 0, 132.9 to 354.3:
44, >354.3: 64; ferritin ng/mL <2000: 0, 2000–
6000: 35, >6000: 50; AST U/L <30: 0, ≥30: 19;
fibrinogen mg/dL >250: 0, ≤250: 30; number of
cytopenic lineages – 1: 0, 2: 24, 3: 34
 One cytologic feature
○ Hemophagocytosis – no: 0, yes: 35
In regards to the validation cohort, the median (IQR)
H-Score in the group with and without secondary HLH
was 230 (203–257) and 125 (91–150), respectively. At
H-Scores of 90, 150, 190, 200, 220, 230, 240, and 250,
the probability for secondary HLH was <1%, 25%, 80%,
88%, 96%, 98%, 99%, and >99%, respectively [13]. Per-
formance of the H-Score was compared against that of
the adapted HLH-2004 criteria in a validation study by
Debaugnies et al. [14]. In their comparison, the HLH-
2004 criteria were shortened to exclude low NK-cell ac-
tivity and soluble IL-2 receptor levels, thereby having
six total criteria instead of the original eight. Among
adult patients at initial presentation, the H-Score out-
performed the modified HLH-2004 criteria at disease
recognition: an H-Score of >138 offered 90% sensitivity,
79% specificity, and 86% diagnostic accuracy compared
to the scenario in which five out of six HLH-2004 cri-
teria are met, where respective values were: 55%, 100%,
and 80%. For established disease, and using maximal
score values, the two diagnostic criteria (using an H-
Score >185) performed similarly.
In addition to meeting at least five out of the eight
criteria in the original HLH-2004 diagnostic guidelines
[5], our patient also had a diagnostic H-Score. Qualify-
ing elements included: known immunosuppression
(SLE on hydroxychloroquine, azathioprine, and ste-
roids), a maximum temperature of 39.6 °C, hepatos-
plenomegaly, triglycerides of 500 mg/dL, AST >30 U/
L, ferritin >6000 ng/mL, fibrinogen nadir <250 mg/dL,
and trilineage cytopenias, earning an H-Score of 302,
consistent with a diagnostic probability of >99%. The
dramatic improvement on all fronts that ensued fol-
lowing initiation of steroid therapy lends further confi-
dence to accuracy of our diagnosis.
Other features consistent with secondary HLH in
our patient include the presence of a euvolemic,
hypo-osmolar hyponatremia with spot urine sodium
of 24 mmol/L, consistent with the syndrome of in-
appropriate antidiuretic hormone (SIADH) [1]. Add-
itionally, our patient manifested CNS involvement
with encephalopathy and agitation requiring intub-
ation for airway protection.
The most common viral drivers for secondary HLH
are EBV, HIV, herpes viruses, cytomegalovirus (CMV),
viral hepatitis, and influenza [1]. In our patient, viral-
testing was negative for these entities. Bacterial, fungal,
and mycobacterial cultures also tested negative. SLE is
also a recognized driver [1], but our patient did not ap-
pear to have signs of active disease, suggesting that the
HLH was secondary to metastatic renal cell carcinoma.
Conclusions
HLH is a life-threatening disorder resulting from im-
munologic hyperactivation that can progress to multior-
gan failure. Early recognition is critical so that progression
may be interrupted. However, this disease entity is likely
under-recognized which is of concern given its high
mortality rate. In pediatric cases, diagnosis is based
upon the HLH-2004 criteria; which, for adult cases,
may be insensitive for diagnosis earlier in the disease
course. The H-Score is a validated diagnostic tool more
appropriate for use among secondary HLH cases. For
pediatric or EBV/lymphomatous cases, chemotherapeu-
tic agents are often added. For adult cases, a high-dose
dexamethasone regimen based upon the HLH-94
protocol may be used.
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